Tue, Jul 22, 2014, 7:50 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Zogenix, Inc. (ZGNX) Message Board

  • ridikulusrumors ridikulusrumors Jan 10, 2014 10:16 PM Flag

    It's down to MNK and ENDP!

    I'm hearing $13.50

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ENDP's buy range for small cap companies is $1m-$500m. Nasdaq lists ZGNX's market cap at $596.75m which puts it out of ENDP's price range. ENDP is overleveraged with all their recent acquisitions while MNK has lots of cash on hand. A $1billion valuation of ZGNX(assuming Zohydro will be a blockbuster) is worth about $7 per share; add Sumavel Dosepro revenues and your looking at close to $9. A multi-billion dollar valuation puts it sky high. I think MNK can afford that.

      If ENDP was to make another acquisition it would probably be BDSI since they currently have a world-wide licensing agreement for BEMA Buprenorphine for pain. BDSI's current market cap is about $236.63m which is in ENDP's price range. A $500m valuation of BDSI (ENDP's high range for small caps) is worth about $13 per share. BDSI has a PDUFA scheduled in June'14 for Bunavail, and phase 3 results for BEMA Buprenorphine due 1Q and 2Q 2014.

      Sentiment: Strong Buy

1.64+0.01(+0.61%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.